This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/national-drug-code-directory/
n12http://www.rxlist.com/
n28http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/bindingdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01080/identifier/pubchem-compound/
n22http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01080
rdf:type
n5:Drug
n5:description
An analogue of gamma-aminobutyric acid, vigabatrin is an irreversible inhibitor of 4-aminobutyrate transaminase, the enzyme responsible for the catabolism of gamma-aminobutyric acid. (From Martindale The Extra Pharmacopoeia, 31st ed). Off-label uses include treatment of cocaine dependence.
n5:dosage
n7:271B620C-363D-11E5-9242-09173F13E4C5 n7:271B620D-363D-11E5-9242-09173F13E4C5 n7:271B620B-363D-11E5-9242-09173F13E4C5 n7:271B620E-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Gram L, Larsson OM, Johnsen A, Schousboe A: Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol. 1989;27 Suppl 1:13S-17S. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2757904 # Browne TR: Pharmacokinetics of antiepileptic drugs. Neurology. 1998 Nov;51(5 Suppl 4):S2-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9818917 # Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T: Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003 Aug;25(4):457-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12883229 # Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller HJ, Rupprecht R: Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001 Nov;25(5):699-703. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11682253 # Tulloch JK, Carr RR, Ensom MH: A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther. 2012 Jan;17(1):31-44. doi: 10.5863/1551-6776-17.1.31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23118657 # Clayton LM, Stern WM, Newman WD, Sander JW, Acheson J, Sisodiya SM: Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Res. 2013 Mar 28. pii: S0920-1211(13)00074-0. doi: 10.1016/j.eplepsyres.2013.02.014. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23541931 # Hawker DD, Silverman RB: Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase. Bioorg Med Chem. 2012 Oct 1;20(19):5763-73. doi: 10.1016/j.bmc.2012.08.009. Epub 2012 Aug 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22944334
n5:group
approved
n5:halfLife
Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); Infants = 5.7 hours; Adults = 7.5 hours; Elderly = 12 - 13 hours
n5:indication
For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome.
owl:sameAs
n27:DB01080 n28:DB01080
dcterms:title
Vigabatrin
adms:identifier
n9:5463 n10:DB01080 n13:50118886 n14:D00535 n15:67386-211-65 n17:C07500 n18:46507052 n20:PA10231 n21:5665 n23:Vigabatrin
n5:mechanismOfAction
Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active.
n5:packager
n19:271B6208-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Eliminated primarily through renal excretion as unchanged drugs (80%).
n5:synonym
Vigabatrina gamma-Vinyl GABA Vigabatrin Vigabatrine Vigabatrinum GVG 4-Amino-5-hexenoic acid gamma-Vinyl-gamma-aminobutyric acid
n5:toxicity
LD50, oral, rat: 3000 mg/kg; Visual field defects may occur following cumulative doses in excess of 2 kg.
n5:volumeOfDistribution
1.1 L/kg
n3:hasAHFSCode
n4:28-12-92
n5:proteinBinding
Not protein bound
foaf:page
n12:sabril-drug.htm n16:vigabatrin.html
n5:IUPAC-Name
n6:271B6213-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6219-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B6218-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B6215-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B6216-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B6217-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B6211-363D-11E5-9242-09173F13E4C5 n6:271B6229-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B620F-363D-11E5-9242-09173F13E4C5 n6:271B6212-363D-11E5-9242-09173F13E4C5 n6:271B622A-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B6210-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n22:N03AG04
n5:H-Bond-Acceptor-Count
n6:271B621F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B6220-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B621A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B621B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B621D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B621C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B621E-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly absorbed following oral administration, absorption is comparable between neonates, infants, and children. Cmax, 50 mg/kg dose, neonates= 14 mg/L; Tmax, 50 mg/kg dose, neonates = 2.1 hours; However, extent of absorption is higher and elimination half life is longer in neonates compared to children and infants. This is because neonates have reduced renal function compared to the aforementioned population groups. AUC, 50 mg/kg dose, neonates = 142.6 ± 44.0 mg/L/hr; Food may slightly decrease the rate (Cmax decreased by 33%, Tmax increased to 2 hours), but not the extent of absorption. Furthermore, vigabatrin does not cross the blood-brain-barrier well, thus high doses are needed.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
60643-86-9
n5:category
n5:clearance
Infants = 2.4 ± 0.8 L/h; Children = 5.7 ± 2.5 L/h
n5:containedIn
n24:271B620A-363D-11E5-9242-09173F13E4C5 n24:271B6209-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B6225-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B6227-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B6228-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B6224-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B6223-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B6226-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B6214-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B6221-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B6222-363D-11E5-9242-09173F13E4C5